公司資料
Agios Pharmaceuticals, Inc. 股價、新聞與催化劑
- 股票代碼:
- AGIO
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
33.63 USD (+0.21%)
收盤價
最後更新: 2026年8月17日
1.58B USD
市值
股價為何變動
As of Aug 17, 2026, AGIO was little changed and closed at $33.63. No new same-company headline was identified in the current news window.
公司概覽
Rare Disease Hematology Company
Agios is a commercial-stage biopharmaceutical company focused on rare diseases, with a foundation in hematology. Its current business is anchored by mitapivat, sold as PYRUKYND and AQVESME, while the company expands into additional rare hematology and metabolic disease programs.
Mitapivat Commercial Expansion
Mitapivat generated $44.7 million in worldwide net revenue in the second quarter of 2026. U.S. revenue was driven by the launch of AQVESME in thalassemia, while ex-U.S. revenue reflected European approval and early demand in Gulf Cooperation Council countries. Mitapivat is now approved for adults with thalassemia in the U.S., Saudi Arabia, United Arab Emirates, and the EU.
Sickle Cell Disease Opportunity
Agios is pursuing mitapivat in sickle cell disease through the FDA accelerated approval pathway. The FDA granted Priority Review for the supplemental NDA, with a PDUFA date of November 1, 2026, and the company has started the REIGNITE confirmatory Phase 3 trial.
Pipeline Diversification
The company is broadening beyond mitapivat. It licensed cevidoplenib, an oral SYK inhibitor for immune thrombocytopenia, and plans Phase 3 development after CMC work. AG-236, an siRNA targeting TMPRSS6, is advancing into Phase 2/3 development for polycythemia vera, while AG-181 is in Phase 1b testing for PKU.
未來催化劑
- FDA PDUFA date for mitapivat in sickle cell disease on November 1, 2026.
- Phase 2 portion initiation for AG-236 in polycythemia vera in the second half of 2026.
- AG-181 Phase 1b data in PKU expected in the second half of 2026.
- Cevidoplenib Phase 3 development in ITP expected to begin in the first half of 2028.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。